Cellular immune responses in asymptomatic human immunodeficiency virus type 1 (HIV-1) infection and effects of vaccination with recombinant envelope glycoprotein of HIV-1

Clinical and Vaccine Immunology

Volumn 13, Issue 1, 2006, Pages 26-32

  Gorse, Geoffrey J ^a,b,c   Simionescu, Ramona E ^b,d   Patel, Gira B ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Division of Infectious Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; MONOCLONAL ANTIBODY CD3; PLACEBO; RECOMBINANT GLYCOPROTEIN GP 120; RECOMBINANT GLYCOPROTEIN GP 160; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS GLYCOPROTEIN;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCING CELL; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 IIIB; HUMAN IMMUNODEFICIENCY VIRUS 1 MN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENT CELL; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VACCINATION;

AIDS VACCINES; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOTHERAPY, ACTIVE; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MALE; VACCINES, SYNTHETIC;

EID: 33645118800     PISSN: 15566811     EISSN: None     Source Type: Journal    
DOI: 10.1128/CVI.13.1.26-32.2006     Document Type: Article

References (33)

1. Barrett, N., A. Mitterer, W. Mundt, J. Eibl, M. Eibl, R. C. Gallo, B. Moss, and F. Dorner. 1989. Large-scale production and purification of a vaccinia recombinant-derived HIV-1 gp160 and analysis of its immunogenicity. AIDS Res. Hum. Retrovir. 5:159-171.
2. Belshe, R. B., M. L. Clements, R. Dolin, B. S. Graham, J. McElrath, G. J. Gorse, D. Schwartz, M. C. Keefer, P. Wright, L. Corey, D. P. Bolognesi, T. J. Matthews, D. M. Stablein, F. S. O'Brien, M. Eibl, F. Dorner, W. Koff, and the National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network. 1993. Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. J. Infect. Dis. 168:1387-1395.
3. + T-cell responses: relationship to viral load in untreated HIV infection. J. Virol. 75:11983-11991.
4. Birx, D. L., L. D. Loomis-Price, N. Aronson, J. Brundage, C. Davis, L. Deyton, R. Garner, F. Gordin, D. Henry, W. Holloway, T. Kerkering, R. Luskin-Hawk, J. McNeil, N. Michael, P. F. Pierce, D. Poretz, S. Ratto-Kim, P. Renzullo, N. Ruiz, K. Sitz, G. Smith, C. Tacket, M. Thompson, E. Tramont, B. Yangco, R. Yarrish, R. R. Redfield, and the rgp160 Phase II Vaccine Investigators. 2000. Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. J. Infect. Dis. 181:881-889.
5. Boyum, A. 1968. Isolation of mononuclear cells and granulocytes from human blood. Scand. J. Clin. Lab. Investig. 21(Suppl. 97):77-89.
6. Dubey, C., M. Croft, and S. L. Swain. 1996. Naïve and effector CD4 T cells differ in their requirements for T cell receptor versus costimulatory signals. J. Immunol. 157:3280-3289.
7. Eron, J. J., Jr., M. A. Ashby, M. F. Giordano, M. Chernow, W. M. Reiter, S. G. Deeks, J. P. Lavelle, M. A. Conant, B. G. Yangco, P. G. Pate, R. A. Torres, R. T. Mitsuyasu, and T. Twaddell. 1996. Randomized trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection. Lancet 348:1547-1551.
8. Gorse, G. J., and R. B. Belshe. 1991. Enhanced lymphoproliferation to influenza A virus following vaccination of older, chronically ill adults with live-attenuated viruses. Scand. J. Infect. Dis. 23:7-17.
9. Gorse, G. J., R. B. Belshe, F. K. Newman, S. E. Frey, and the NIAID AIDS Vaccine Clinical Trials Network. 1992. Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant gp160. Vaccine 10:383-388.
10. + T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2. J. Virol. 77:10900-10909.
11. + T lymphocyte immune function in long-term survivors of AIDS-related CMV end-organ disease who are receiving potent antiretroviral therapy. J. Infect. Dis. 183:1399-1404.
12. Jenkins, M. K. 2003. Peripheral T-lymphocyte responses and function, p. 303-319. In W. E. Paul (ed.), Fundamental immunology, 5th ed. Lippincott Williams and Wilkins, Philadelphia, Pa.
13. Kalams, S. A. 2003. Cellular immunity for prevention and clearance of HIV infection. Curr. Mol. Med. 3:195-208.
14. Kalams, S. A., S. P. Buchbinder, E. S. Rosenberg, J. M. Billingsley, D. S. Colbert, N. G. Jones, A. K. Shea, A. K. Trocha, and B. D. Walker. 1999. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J. Virol. 73:6715-6720.
15. Kalams, S. A., and B. D. Walker. 1998. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J. Exp. Med. 188:2199-2204.
16. + T-cell responses in HIV-1-infected subjects with sustained virologic control after highly active antiretroviral therapy. J. Acquir. Immun. Defic. Syndr. 36:594-599.
17. + T cell proliferation. Proc. Natl. Acad. Sci. USA 98:13878-13883.
18. Moss, R. B., C. Brandt, W. K. Giermakowska, J. R. Savary, G. Theofan, M. Zanetti, D. J. Carlo, and M. R. Wallace. 2003. HIV-specific immunity during structured antiviral drug treatment interruption. Vaccine 21:1066-1071.
19. + T cells and HIV-1-specific lymphoproliferation in HIV-1-infected subjects with active viral replication. J. Virol. 76:5925-5936.
20. Papasavvas, E., J. K. Sandberg, R. Rutstein, E. C. Moore, A. Mackiewicz, B. Thiel, M. Pistilli, R. R. June, K. A. Jordan, R. Gross, V. C. Maino, D. F. Nixon, and L. J. Montaner. 2003. Presence of human immunodeficiency virus-1-specific CD4 and CD8 cellular immune responses in children with full or partial virus suppression. J. Infect. Dis. 188:873-882.
21. + T-cell immunity to HIV infection. Clin. Lab. Med. 22:773-797.
22. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat. Med. 5:518-525.
23. Pontesilli, O., E. C. Guerra, A. Ammassari, C. Tomino, M. Carlesimo, A. Antinori, E. Tamburrini, A. Prozzo, A. C. Seeber, S. Vella, L. Ortona, F. Aiuti, and the VaxSyn Protocol Team. 1998. Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. AIDS 12:473-480.
24. Ratto-Kim, S., R. P. Garner, J. H. Kim, L. L. Jagodzinski, N. L. Michael, R. Paris, R. R. Redfield, and D. L. Birx. 2004. Prospective analyses of HIV-1-specific proliferative responses, recall antigen proliferative responses, and clinical outcomes in an HIV-1-seropositive cohort. J. Infect. Dis. 189:1988-1995.
25. Ratto-Kim, S., K. V. Sitz, R. P. Garner, J. H. Kim, C. Davis, N. Aronson, N. Ruiz, K. Tencer, R. R. Redfield, and D. L. Birx. 1999. Repeated immunization with recombinant gp160 human immunodeficiency virus (HIV) envelope protein in early HIV-1 infection: evaluation of the T cell proliferative response. J. Infect. Dis. 179:337-344.
26. Redfield, R. R., D. L. Birx, N. Ketter, E. Tramont, V. Polonis, C. Davis, J. F. Brundage, G. Smith, S. Johnson, A. Fowler, T. Wierzba, A. Shafferman, F. Volvovitz, C. Oster, D. S. Burke, and the Military Medical Consortium for Applied Retroviral Research. 1991. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. N. Engl. J. Med. 324:1677-1684.
27. + T cell responses associated with control of viremia. Science 278:1447-1450.
28. Schooley, R. T., C. Spino, D. Kuritzkes, B. D. Walker, F. T. Valentine, M. S. Hirsch, E. Cooney, G. Friedland, S. Kundu, T. C. Merigan, Jr., M. J. McElrath, A. Collier, S. Plaeger, R. Mitsuyasu, J. Kahn, P. Haslett, P. Uherova, V. deGruttola, S. Chiu, B. Zhang, G. Jones, D. Bell, N. Ketter, T. Twaddell, D. Chernoff, M. Rosandich, and the AIDS Clinical Trials Group 209 and 214 Study Teams. 2000. Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214. J. Infect. Dis. 182:1357-1364.
29. Suni, M. A., L. J. Picker, and V. C. Maino. 1998. Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry. J. Immunol. Methods 212:89-98.
30. 3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137). J. Infect. Dis. 173:1336-1346.
31. Wahren, B., G. Bratt, C. Persson, B. Leven, J. Hinkula, G. Gilljam, S. Nordlund, L. Eriksson, F. Volvovitz, P. A. Broliden, and E. Sandstrom. 1994. Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160. J. Acquir. Immune Defic. Syndr. 7:220-229.
32. + T cell proliferative ability but not loss of human immunodeficiency virus type 1 specificity equates with progression to disease. J. Infect. Dis. 182:792-798.
33. Wright, P. F., J. S. Lambert, G. J. Gorse, R.-H. Hsieh, M. J. McElrath, K. Weinhold, D. W. Wara, E. L. Anderson, M. C. Keefer, S. Jackson, L. J. Wagner, D. P. Francis, P. E. Fast, J. McNamara, and the AIDS Vaccine Evaluation Group. 1999. Immunization with envelope MN rgp120 vaccine in human immunodeficiency virus-infected pregnant women. J. Infect. Dis. 180:1080-1088.